ProCE Banner Activity

How Should We Individualize Management for Patients With Type 2 Diabetes and CKD?

Clinical Thought

Dr Vivian Fonseca provides insights on how to tailor the management of type 2 diabetes (T2D) and chronic kidney disease (CKD) for your individual patients, including treatment recommendations for high-risk patients and those with concurrent cardiovascular disease.

Released: September 14, 2022

Expiration: September 13, 2023

Share

Faculty

Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Vivian Fonseca, MD, FRCP: research support (paid to institution): Fractyl, Jaguar Gene Therapy; constultant/speaker: Abbott, Asahi Astra-Zeneca, Novo Nordisk, Sanofi; stock/stock options: Abbott, Amgen, BRAVO4Health, Mellitus Health; patent: BRAVO Risk Engine for Predicting Diabetes Complications.